Update
$NeuroSense Therapeutics (NRSN.US)$ NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) on Wednesday said it is currently in advanced discussions with several multi-billion-dollar pharmaceutical companies regarding a potential strategic partnership to develop and commercialize its lead drug candidate, PrimeC, for Amyotrophic Lateral Sclerosis (ALS).
These discussions, based on non-binding terms, indicate the potential for substantial financial benefits to NeuroSense, including upfront payments, milestone payments, and royalty payments as part of an agreement.
NeuroSense anticipates receiving terms from these discussions in the fourth quarter of 2024; however, there can be no assurance that terms will be finalized with any of the pharmaceutical companies, the timing, what the final terms would be, if any, or that a definitive agreement will be reached.
These discussions, based on non-binding terms, indicate the potential for substantial financial benefits to NeuroSense, including upfront payments, milestone payments, and royalty payments as part of an agreement.
NeuroSense anticipates receiving terms from these discussions in the fourth quarter of 2024; however, there can be no assurance that terms will be finalized with any of the pharmaceutical companies, the timing, what the final terms would be, if any, or that a definitive agreement will be reached.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
